SG11201807041PA - Improved preparations of adult liver progenitor cells - Google Patents
Improved preparations of adult liver progenitor cellsInfo
- Publication number
- SG11201807041PA SG11201807041PA SG11201807041PA SG11201807041PA SG11201807041PA SG 11201807041P A SG11201807041P A SG 11201807041PA SG 11201807041P A SG11201807041P A SG 11201807041PA SG 11201807041P A SG11201807041P A SG 11201807041PA SG 11201807041P A SG11201807041P A SG 11201807041PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- neuve
- universite
- place
- preparations
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 4
- 210000004185 liver Anatomy 0.000 title abstract 3
- 210000000130 stem cell Anatomy 0.000 title abstract 3
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 208000018592 inherited blood coagulation disease Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5067—Liver cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/14—Coculture with; Conditioned medium produced by hepatocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2531/00—Microcarriers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16158327 | 2016-03-02 | ||
| PCT/EP2017/054859 WO2017149059A1 (en) | 2016-03-02 | 2017-03-02 | Improved preparations of adult liver progenitor cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807041PA true SG11201807041PA (en) | 2018-09-27 |
Family
ID=55696855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807041PA SG11201807041PA (en) | 2016-03-02 | 2017-03-02 | Improved preparations of adult liver progenitor cells |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190046584A1 (es) |
| EP (1) | EP3423566A1 (es) |
| JP (1) | JP2019506890A (es) |
| KR (1) | KR20180114073A (es) |
| CN (1) | CN108779440A (es) |
| AU (1) | AU2017225825A1 (es) |
| BR (1) | BR112018067597A8 (es) |
| CA (1) | CA3013427A1 (es) |
| EA (1) | EA039743B1 (es) |
| IL (1) | IL261383A (es) |
| MA (1) | MA45274A (es) |
| MX (1) | MX2018010508A (es) |
| SG (1) | SG11201807041PA (es) |
| WO (1) | WO2017149059A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6474394B2 (ja) | 2013-07-05 | 2019-02-27 | ユニベルシテ カトリック ドゥ ルーベン | ヒト成体肝臓幹細胞由来の馴化培地および肝臓障害の治療におけるその使用 |
| WO2020120666A1 (en) | 2018-12-14 | 2020-06-18 | Promethera Biosciences S.A./N.V. | Liver progenitor cells expressing hla-g, and method for obtaining these cells compositions comprising said cells and their use |
| KR20210116469A (ko) | 2018-12-14 | 2021-09-27 | 프로메테라 테라푸틱스 에스에이 | Hla-e를 발현하는 간 전구 세포를 포함하는 세포 조성물 |
| EP3947645A1 (en) | 2019-03-26 | 2022-02-09 | Promethera Therapeutics Sa | Adult liver progenitor cells for treating non-alcoholic fatty liver disease |
| KR20220004977A (ko) | 2019-03-26 | 2022-01-12 | 프로메테라 테라푸틱스 에스에이 | 만성 간부전의 급성 악화를 치료하기 위한 성체 간 전구 세포 |
| ES2966620T3 (es) | 2019-04-30 | 2024-04-23 | Cellaion Sa | Preparación de células progenitoras hepáticas alogénicas humanas |
| EP3963049A1 (en) | 2019-04-30 | 2022-03-09 | Promethera Therapeutics Sa | Preparation of human allogeneic liver-derived progenitor cells |
| AU2020364951A1 (en) | 2019-10-09 | 2022-05-26 | Cellaïon SA | Use of liver progenitor or stem cells, lysates thereof, and/or conditioned medium in disorders characterized by vascular hyperpermeability |
| EP3881853A1 (en) | 2020-03-20 | 2021-09-22 | Promethera Therapeutics Sa | Human allogeneic liver-derived progenitor cells for use in the treatment of inflammatory and infectious lung diseases and systemic inflammation |
| CN111778268B (zh) * | 2020-06-03 | 2022-06-21 | 武汉仝干医疗科技股份有限公司 | 增强解毒功能基因片段及改造的HepG2细胞 |
| WO2023180122A1 (en) | 2022-03-24 | 2023-09-28 | Université Catholique de Louvain | Use of human allogenic liver-derived progenitor cells for treating and/or preventing cellular senescence |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006126219A1 (en) | 2005-05-26 | 2006-11-30 | Fresenius Medical Care Deutschland G.M.B.H. | Liver progenitor cells |
| ES2359874T5 (es) * | 2005-12-21 | 2014-12-12 | Universite Catholique De Louvain | Células madre hepáticas aisladas |
| EP2281875B1 (en) * | 2005-12-21 | 2018-03-21 | Université Catholique De Louvain | Isolated liver stem cells |
| WO2009139419A1 (ja) * | 2008-05-14 | 2009-11-19 | 公立大学法人横浜市立大学 | ヒト肝幹細胞、その調製方法、分化誘導方法及び利用方法 |
| US8415149B2 (en) * | 2010-05-06 | 2013-04-09 | Gwo Xi Stem Cell Applied Technology Co., Ltd. | Hepatic progenitor cells and uses thereof |
| ES2726802T3 (es) * | 2012-01-25 | 2019-10-09 | Univ Catholique Louvain | Composiciones y métodos para el trasplante celular |
| JP6474394B2 (ja) * | 2013-07-05 | 2019-02-27 | ユニベルシテ カトリック ドゥ ルーベン | ヒト成体肝臓幹細胞由来の馴化培地および肝臓障害の治療におけるその使用 |
| EP3620514A1 (en) * | 2013-08-28 | 2020-03-11 | Promethera Biosciences S.A. / N.V. | Method for producing adult liver progenitor cells |
-
0
- MA MA045274A patent/MA45274A/fr unknown
-
2017
- 2017-03-02 CN CN201780014428.3A patent/CN108779440A/zh active Pending
- 2017-03-02 US US16/079,694 patent/US20190046584A1/en not_active Abandoned
- 2017-03-02 MX MX2018010508A patent/MX2018010508A/es unknown
- 2017-03-02 WO PCT/EP2017/054859 patent/WO2017149059A1/en active Application Filing
- 2017-03-02 EP EP17711579.7A patent/EP3423566A1/en not_active Withdrawn
- 2017-03-02 EA EA201891913A patent/EA039743B1/ru unknown
- 2017-03-02 CA CA3013427A patent/CA3013427A1/en not_active Abandoned
- 2017-03-02 SG SG11201807041PA patent/SG11201807041PA/en unknown
- 2017-03-02 KR KR1020187024591A patent/KR20180114073A/ko not_active IP Right Cessation
- 2017-03-02 BR BR112018067597A patent/BR112018067597A8/pt not_active IP Right Cessation
- 2017-03-02 AU AU2017225825A patent/AU2017225825A1/en not_active Abandoned
- 2017-03-02 JP JP2018546539A patent/JP2019506890A/ja active Pending
-
2018
- 2018-08-26 IL IL261383A patent/IL261383A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017149059A1 (en) | 2017-09-08 |
| US20190046584A1 (en) | 2019-02-14 |
| AU2017225825A1 (en) | 2018-08-16 |
| KR20180114073A (ko) | 2018-10-17 |
| EA201891913A1 (ru) | 2019-02-28 |
| MA45274A (fr) | 2019-01-09 |
| BR112018067597A2 (pt) | 2019-01-08 |
| JP2019506890A (ja) | 2019-03-14 |
| EP3423566A1 (en) | 2019-01-09 |
| MX2018010508A (es) | 2018-11-09 |
| IL261383A (en) | 2018-10-31 |
| CN108779440A (zh) | 2018-11-09 |
| EA039743B1 (ru) | 2022-03-05 |
| CA3013427A1 (en) | 2017-09-08 |
| BR112018067597A8 (pt) | 2019-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807041PA (en) | Improved preparations of adult liver progenitor cells | |
| SG11201809041TA (en) | Compositions and methods for selective protein expression | |
| SG11201903928WA (en) | Mesenchymal stem cells populations, their products, and use thereof | |
| SG11201806340YA (en) | Zika virus vaccine | |
| SG11201805993UA (en) | Genetically modified non-human mammals by multi-cycle electroporation of cas9 protein | |
| SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
| SG11201807195VA (en) | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity | |
| SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201901628XA (en) | Methods and compositions for spinal cord cells | |
| SG11201807051VA (en) | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy | |
| SG11201408405WA (en) | Engineered three-dimensional connective tissue constructs and methods of making the same | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201901961SA (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| SG11201805052YA (en) | Therapeutic methods using erythrocytes | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion |